MLTX INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In MLTX To Contact Him Directly To Discuss Their Options

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake Immunotherapeutics due to allegations of violations of federal securities laws, particularly following disappointing clinical trial results that led to a significant drop in the company's stock price [2][3][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $75,000 in MoonLake between March 10, 2024, and September 29, 2025, to discuss their legal options [1][2]. - A federal securities class action has been filed against MoonLake, with a deadline of December 15, 2025, for investors to seek the role of lead plaintiff [2][5]. Group 2: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives made false or misleading statements regarding the efficacy of their product SLK compared to BIMZELX, including claims about molecular targets and clinical benefits [3]. - Specific allegations include that SLK shares the same molecular targets as BIMZELX and that its unique structure does not provide superior clinical benefits [3]. Group 3: Stock Price Impact - Following the announcement of the Phase 3 VELA program results on September 28, 2025, which indicated that SLK did not demonstrate competitive efficacy relative to BIMZELX, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4].